A year has 8,760 hours. Support the campaign
Vitruvian Shield
Hybrid trial platform

Hybrid trial platform components for CROs and sponsors

One platform that replaces several separate vendors for hybrid studies. CTMS, EDC, eConsent, ePRO, remote patient monitoring and the CONNECT integration layer can be used individually or together.

Why consolidate

Fewer systems for sites. One dataset for the study team.

One platform in place of several vendors

Sites and study teams work in one system for consent, data capture, patient-reported outcomes and monitoring.

One component or all of them

Add eConsent or ePRO beside the EDC you already use, or run the whole study on the platform. The CONNECT integration layer links the components to your existing systems.

ICH E6(R3) readiness

The ICH E6(R3) principles and Annex 1 have applied in the EU since 23 July 2025. Annex 2, on decentralised and pragmatic trial elements, applies from 15 January 2027.

The platform is designed to support sponsors and CROs in meeting these expectations: remote consent, data from digital health technologies and investigator oversight of activities outside the site. This is a design statement, not a certification.

Sponsor validation and vendor-qualification pack

The documentation sponsors and CROs need to qualify the platform as a vendor.

Delivery schedule agreed in the written proposal.

CRO partnership

Small and mid-size CROs can offer the platform to their sponsors under partner terms. The CRO keeps the sponsor relationship and runs the study; Vitruvian Shield supplies and supports the platform.

Proposal and study set-up

A written proposal within one week of scoping. Your study set-up plan and go-live date are agreed in the written proposal, before any commitment.

One platform, three service levels

Level 1

You run it

You run the study on the platform with your own people and sites. We set the platform up and support it.

Discuss this level: You run it

Level 2

We run it

Level 1 plus data management, monitoring and the annual report by Vitruvian Shield.

Discuss this level: We run it

Level 3

We bring the hospital

Level 2 plus subcontracted clinical sites.

Discuss this level: We bring the hospital

The level is chosen at scoping and set out in the written proposal.

How we work

Who it is for

Teams that need hybrid components without building their own tools.

Small and mid-size CROs

Contract research organisations that need a modern platform for hybrid studies without building their own tools.

Academic medical centres

University hospitals and academic research networks running investigator-initiated trials and observational studies.

Investigator-initiated studies

Individual principal investigators funded through grants (Innosuisse, NIH, Horizon Europe) who need a turnkey platform.

Hospital research units

In-house research units at hospital networks that want to standardise data capture across the institution.

Questions and answers

Questions about the hybrid trial platform

What is the hybrid trial platform?

One platform that replaces several separate vendors for hybrid studies: CTMS, EDC, eConsent, ePRO, remote patient monitoring and the CONNECT integration layer. The components can be used individually or together. The configuration for CROs and academic medical centres is called Vitruvian Shield RESEARCH.

How does RESEARCH differ from CONNECT?

RESEARCH is the study configuration for CROs and academic centres. CONNECT is the integration layer for sponsors and CROs on Medidata, Veeva or Oracle stacks who want to plug wearables, biosignal streams and study modules into the enterprise systems they already run.

Who runs the study?

Three layers run a study: sponsors own the study and the EDC, CROs run the study, and vendors supply the evidence layer. Vitruvian Shield sits in the vendor layer. Three service levels define how much of the operation the Vitruvian Shield team takes on.

What evidence exists for the platform in real studies?

Studies in preparation include an oncology electronic survey study at ULS Coimbra and PT-EPI-DCT-002, decentralised seizure monitoring in adult epilepsy, at ULS Santa Maria. An independent key-opinion-leader expert review was completed on 28 May 2026 through Instituto Pedro Nunes; it is an expert opinion, not a study result. No peer-reviewed output has been published yet. ULS Santa Maria is a partner under a non-binding letter of intent.

Which data exports are provided?

The platform is designed to deliver CDISC and HL7 FHIR exports so home-collected data lands in the sponsor's existing EDC and analysis environment with its provenance and audit trail intact.

Talk to us about your next study

Tell us about the protocol, the countries and the devices. We will show you how the platform would run it.